Latest Share Chat

DIRECTOR DEALINGS: e-Therapeutics Finance Director Buys 150,000 Shares

Wed, 21st Jan 2015 11:42

LONDON (Alliance News) - e-Therapeutics PLC said Finance Director Steve Medlicott bought 150,000 shares at a price of 25.25 pence per share Wednesday.

Following this transaction, Medlicott's direct beneficial interest is 250,000 shares, representing 0.09% of the total issued share capital.

Shares in the drug discovery and development company were down 3.9% at 25.00p Wednesday.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Related Shares

More News

10 Apr 2024 12:32

e-Therapeutics proposes £29m fundraising, delisting from AIM

(Sharecast News) - RNAi medicines data and development specialist e-Therapeutics proposed a fundraise and its delisting from AIM on Wednesday.

10 Apr 2024 10:48

e-Therapeutics says company faces lack of interest as UK listing

(Alliance News) - e-Therapeutics PLC on Wednesday announced its intention to cancel its admission to AIM and instead explore the option of listing on ...

16 Jan 2024 10:34

IN BRIEF: e-Therapeutics shares rise on strong financial year

e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Says 2023 was

27 Dec 2023 10:27

IN BRIEF: e-Therapeutics shares to cease trading on OTCQX

e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Says that its shares will cease to trade on the OTCQX Best Market i...

2 Nov 2023 14:34

EARNINGS AND TRADING: Kanabo inks CBD deal, Taseko boosts production

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...